An NS5A single optimized method to determine genotype, subtype and resistance profiles of Hepatitis C strains-Reference-Cited by-同舟云学术

An NS5A single optimized method to determine genotype, subtype and resistance profiles of Hepatitis C strains

Published:2017-07-20 Issue:7 Volume:12 Page:e0179562
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Andre-Garnier Elisabeth^ORCID,Besse Bernard,Rodallec Audrey,Ribeyrol Olivier,Ferre Virginie,Luco Caroline,Le Guen Laura,Bourgeois Nathalie,Gournay Jérôme,Billaud Eric,Raffi François,Coste-Burel Marianne,Imbert-Marcille Berthe-Marie

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference25 articles.

1. Treatment of chronic hepatitis C: current and future;J-M Pawlotsky;Curr Top Microbiol Immunol,2013

2. New antiviral therapies for chronic hepatitis C;T Kanda;Hepatol Int,2010

3. New horizons in hepatitis C antiviral therapy with direct-acting antivirals;A Aghemo;Hepatology,2013

4. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource;DB Smith;Hepatol Baltim Md,2014

5. New hepatitis C therapies;J-M Pawlotsky;Semin Liver Dis,2014

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Looking at the Molecular Target of NS5A Inhibitors throughout a Population Highly Affected with Hepatitis C Virus;Pathogens;2023-05-24

2. Hepatitis C subtyping assay failure in UK patients born in sub‐Saharan Africa: Implications for global treatment and elimination;Journal of Medical Virology;2022-10-08

3. Characterization of primary direct-acting antiviral (DAA) drugs resistance mutations in NS5A/NS5B regions of hepatitis C virus with genotype 1a and 1b from patients with chronic hepatitis;Revista do Instituto de Medicina Tropical de São Paulo;2022

4. Hepatitis C subtyping assay failure in UK patients born in Sub-Saharan Africa: implications for global treatment and elimination;2021-12-15

5. Efficacy of 8 weeks elbasvir/grazoprevir regimen for naïve-genotype 1b, HCV infected patients with or without glucose abnormalities: Results of the EGG18 study;Digestive and Liver Disease;2021-09